Eastern and South-Eastern Asia vs Saudi Arabia: Percentage of bloodstream infection due to methicillin-resistant
Eastern and South-Eastern Asia
41.3%
in 2022
Saudi Arabia
52.0%
in 2022
Eastern and South-Eastern Asia rank
9th
Saudi Arabia rank
12th
Percentage of bloodstream infection due to methicillin-resistant over time
- Eastern and South-Eastern Asia
- Saudi Arabia
How they compare
Saudi Arabia currently reports 52.0% against 41.3% in Eastern and South-Eastern Asia, a difference of 10.7%.
That makes Saudi Arabia's figure about 1.3 times Eastern and South-Eastern Asia's.
Across all 6 years both countries report, Saudi Arabia has been ahead every year.
Eastern and South-Eastern Asia ranks 9th and Saudi Arabia ranks 12th of 15 groups.
Saudi Arabia has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Eastern and South-Eastern Asia | Saudi Arabia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 32.9% | 42.8% | 9.9% | Saudi Arabia |
| 2020s | 37.5% | 67.5% | 30.0% | Saudi Arabia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher percentage of bloodstream infection due to methicillin-resistant, Eastern and South-Eastern Asia or Saudi Arabia?
- Saudi Arabia, at 52.0% against 41.3% in Eastern and South-Eastern Asia as of 2022.
- What is the difference in percentage of bloodstream infection due to methicillin-resistant between Eastern and South-Eastern Asia and Saudi Arabia?
- 10.7%, with Saudi Arabia ahead.
- How many years of comparable data are there for Eastern and South-Eastern Asia and Saudi Arabia?
- 6 years are reported by both, from 2017 to 2022.
- How do Eastern and South-Eastern Asia and Saudi Arabia rank globally for percentage of bloodstream infection due to methicillin-resistant?
- Eastern and South-Eastern Asia ranks 9th and Saudi Arabia ranks 12th of 15 groups.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.